PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCholestyramine
Cholestyramine
Cholestyramine, Locholest, Prevalite (cholestyramine) is a small molecule pharmaceutical. Cholestyramine was first approved as Questran on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cholestyramine, Locholest, Prevalite (discontinued: Cholestyramine, Cholybar, Questran)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cholestyramine
Tradename
Company
Number
Date
Products
QUESTRANBristol Myers SquibbN-016640 DISCN1982-01-01
2 products, RLD
QUESTRAN LIGHTBristol Myers SquibbN-019669 DISCN1988-12-05
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cholestyramineANDA2024-08-23
cholestyramine for oral suspensionANDA2023-01-09
cholestyramine lightANDA2024-07-24
cholestyramine powder for suspensionANDA2024-04-12
prevaliteANDA2020-06-18
questranANDA2019-11-01
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AC: Bile acid sequestrants
— C10AC01: Colestyramine
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_0003124——13116
Healthy volunteers/patients———1——2—3
DiarrheaD003967HP_0002014R19.7———112
Malabsorption syndromesD008286EFO_0009554K90—1—1—2
Diabetes mellitusD003920HP_0000819E08-E13———112
Kidney diseasesD007674EFO_0003086N08——11—2
Diabetic neuropathiesD003929EFO_1000783————1—1
Diabetic retinopathyD003930EFO_0003770————1—1
Ankylosing spondylitisD013167EFO_0003898M45———1—1
SpondylarthritisD025241—————1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hyperlipoproteinemia type iiD006938EFO_0004911E78.00—13——4
Cardiovascular diseasesD002318HP_0001626——13——4
Coronary diseaseD003327———13——4
Myocardial ischemiaD017202EFO_1001375I20-I25—13——4
Heart diseasesD006331EFO_0003777I51.9—13——4
Multiple sclerosisD009103EFO_0003885G351—2——3
IschemiaD007511EFO_0000556———3——3
SclerosisD012598————2——2
Graves diseaseD006111EFO_0004237E05.0——1—12
HyperthyroidismD006980—E05.9——1—12
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107HP_0002910K70-K7711———2
Breast neoplasmsD001943EFO_0003869C5011———1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
Fatty liverD005234EFO_0003934——1———1
Short bowel syndromeD012778—K90.82—1———1
SyndromeD013577———1———1
Multiple myelomaD009101—C90.0—1———1
Plasma cell neoplasmsD054219———1———1
Smoldering multiple myelomaD000075122———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230——1———12
MicrobiotaD064307——1————1
Renal insufficiencyD051437HP_0000083N191————1
Biliary liver cirrhosisD008105—K74.31————1
CholestasisD002779HP_0001396K83.11————1
Intrahepatic cholestasisD002780——1————1
Alagille syndromeD016738EFO_0004151Q44.711————1
NeoplasmsD009369—C801————1
Hepatocellular carcinomaD006528—C22.01————1
Liver neoplasmsD008113EFO_1001513C22.01————1
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colonic neoplasmsD003110—C18————11
HyperlipidemiasD006949HP_0003077E78.5————11
HyperlipoproteinemiasD006951HP_0010980—————11
Carotid stenosisD016893——————11
Carotid endarterectomyD016894——————11
ObesityD009765EFO_0001073E66.9————11
Bariatric surgeryD050110——————11
Abdominal obesityD056128HP_0001956—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCholestyramine
INNcolestyramine
Description
Colestyramine (INN) or cholestyramine (USAN) (trade names Questran, Questran Light, Cholybar, Olestyr) is a bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its reabsorption. It is a strong ion exchange resin, which means it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID11041-12-6
RxCUI—
ChEMBL IDCHEMBL1201625
ChEBI ID—
PubChem CID70695640
DrugBankDB01432
UNII ID4B33BGI082 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cholestyramine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,283 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,562 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use